692 terminated. 692 Phase 2, 147 Phase 1, 46 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 692 | Terminated 692 |
| Phase 1 | 147 | Terminated 147 |
| Phase 3 | 46 | Terminated 46 |
Follow Gastrointestinal Diseases: new trials by email Literature Review of Gastrointestinal Diseases trials Research Report on Gastrointestinal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 4SCAR-CD44v6 T Cell Therapy Targeting Cancer CD44v6-specific CAR gene-engineered T cells - Cancers Which Are CD44v6 Positive | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2026-06-01 | 2026-11-03 |
| A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Disease or Ulcerative Colitis (SPECIFI-IBD-LTS) balinatunfib, balinatunfib-matching placebo - Colitis Ulcerative, Crohn's Disease | Phase 2 | Terminated | Sanofi | 7 | 2026-05-19 | 2026-10-22 |
| A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer PD-1 vaccine IMU-201 (PD1-Vaxx) - Colorectal Cancer | Phase 2 | Terminated | University of Southampton | 3 | 2025-06-16 | 2026-06-24 |
| A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation PRT3789, pembrolizumab - Advanced Solid Tumor, Esophageal Cancer | Phase 2 | Terminated | Prelude Therapeutics Incorporated | 6 | 2025-06-03 | 2026-02-02 |
| A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis SAR441566, SAR441566 matching Placebo - Colitis Ulcerative | Phase 2 | Terminated | Sanofi | 170 | 2025-03-28 | 2026-10-21 |
| A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. SAR441566, SAR441566 matching Placebo - Crohn's Disease | Phase 2 | Terminated | Sanofi | 105 | 2024-12-10 | 2026-10-13 |
| A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal Cancers AUR109 200mg, AUR109 300mg, AUR109 400mg - Ovarian Cancer, Colorectal Cancer | Phase 2 | Terminated | Aurigene Discovery Technologies Limited | 29 | 2024-11-09 | 2026-04-17 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) Vixarelimab, Placebo - Ulcerative Colitis | Phase 2 | Terminated | Genentech, Inc. | 79 | 2024-05-01 | 2026-02-24 |
| A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in Patients With Gastric or GEJ Cancer Fluorouracil, Leucovorin, Oxaliplatin - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Terminated | Baylor College of Medicine | 3 | 2024-03-06 | 2026-04-09 |
| Osteopathic Manipulative Treatment for Gastro-oesophageal Reflux Disease Osteopathic manipulative treatment (OMT) - Gastro-oesophageal Reflux Disease | Phase 2 | Terminated | Studio Osteopatico Busto Arsizio | 26 | 2024-02-18 | 2026-07-07 |
| Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D). CIN-103, Placebo - Irritable Bowel Syndrome With Diarrhea | Phase 2 | Terminated | CinPhloro Pharma, LLC | 421 | 2023-12-28 | 2025-12-15 |
| A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors BMS-986466, Adagrasib, Cetuximab - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 5 | 2023-11-09 | 2025-07-22 |
| KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer KN046, regorafenib - Colorectal Cancer | Phase 2 | Terminated | Peking University Cancer Hospital & Institute | 20 | 2023-10-26 | 2026-11-03 |
| Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma Infigratinib - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Terminated | LianBio LLC | 6 | 2023-10-19 | 2024-08-14 |
| A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer Ompenaclid, Placebo, Bevacizumab - Colorectal Cancer, Metastatic Colon Cancer | Phase 2 | Terminated | Inspirna, Inc. | 76 | 2023-10-10 | 2026-02-20 |
| Study of ExoFlo for the Treatment of Perianal Fistulas ExoFlo, Local injection of normal saline - Perianal Fistula, Crohn's Disease | Phase 1 / Phase 2 | Terminated | Direct Biologics, LLC | 5 | 2023-08-28 | 2026-08-11 |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy Ozanimod - Crohn Disease | Phase 2 / Phase 3 | Terminated | Bristol-Myers Squibb | 5 | 2023-08-22 | 2025-04-22 |
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC RP2, RP3, atezolizumab - Refractory Metastatic Colorectal Cancer, pMMR | Phase 2 | Terminated | Replimune, Inc. | 5 | 2023-06-29 | 2026-02-02 |
| A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer | Phase 2 | Terminated | MacroGenics | 192 | 2023-06-13 | 2026-02-09 |
| 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors - Cervical Cancer, Colorectal Cancer | Phase 2 | Terminated | Telix Pharmaceuticals (Innovations) Pty Ltd | 11 | 2023-06-06 | 2025-07-10 |
Showing 20 of 692. Sign in to see all of them.
Colorectal Neoplasms (231) · Stomach Neoplasms (100) · Colonic Neoplasms (77) · Rectal Neoplasms (76) · Crohn Disease (71) · Esophageal Neoplasms (70) · Colitis, Ulcerative (61) · Neoplasm Metastasis (53) · Neoplasms (43) · Carcinoma, Non-Small-Cell Lung (39) · Breast Neoplasms (34) · Inflammatory Bowel Diseases (31) · Ovarian Neoplasms (30) · Pancreatic Neoplasms (29) · Gastrointestinal Neoplasms (22)
Digestive System Diseases (685) · Intestinal Diseases (479) · Digestive System Neoplasms (449) · Neoplasms by Site (448) · Neoplasms (430) · Gastrointestinal Neoplasms (429) · Colonic Diseases (340) · Intestinal Neoplasms (298) · Rectal Diseases (284) · Gastroenteritis (165) · Stomach Diseases (114) · Pathological Conditions, Signs and Symptoms (112) · Neoplasms by Histologic Type (106) · Esophageal Diseases (104)
Fluorouracil (74) · Oxaliplatin (67) · Capecitabine (62) · Irinotecan (58) · Leucovorin (57) · Bevacizumab (48) · Cetuximab (42) · Cisplatin (27) · Radiotherapy (25) · pembrolizumab (23) · Docetaxel (16) · Paclitaxel (16) · Panitumumab (13) · Nivolumab (12) · Trastuzumab (11)
National Cancer Institute (NCI) (29) · Pfizer (11) · Hoffmann-La Roche (10) · Roswell Park Cancer Institute (10) · M.D. Anderson Cancer Center (9) · Novartis Pharmaceuticals (9) · Washington University School of Medicine (8) · AstraZeneca (7) · Bristol-Myers Squibb (7) · Georgetown University (7) · Mayo Clinic (7) · University of Utah (7) · Amgen (6) · Gilead Sciences (6) · Sanofi (6)
United States (442) · France (94) · Germany (91) · Spain (76) · Canada (74) · Italy (69) · Belgium (67) · United Kingdom (63) · South Korea (59) · Australia (58) · Poland (58) · China (41) · Netherlands (41) · Hungary (38) · Czechia (36)
Amy Lightner, MD (4) · David S Schrump, M.D. (3) · Kathy Bohannon (3)
PMID 28712102, PMID 31527168, PMID 12219789, PMID 12556782, PMID 12809831, PMID 17945036, PMID 17960014, PMID 18197583, PMID 18829790, PMID 18845990, PMID 19302707, PMID 19333040, PMID 19525947, PMID 19643599, PMID 19738454, PMID 20857170, PMID 20947884, PMID 20975604, PMID 21131921, PMID 21453880, PMID 21516509, PMID 21702914, PMID 21892283, PMID 22198309, PMID 22294255, PMID 22431703, PMID 22595313, PMID 22610353, PMID 22619366, PMID 22825365, PMID 23163616, PMID 23443801, PMID 23622977, PMID 23848826, PMID 24237037, PMID 24244261, PMID 24244687, PMID 24512954, PMID 24824852, PMID 25271602, PMID 25530111, PMID 25926532, PMID 26109878, PMID 26119226, PMID 26784946, PMID 27342748, PMID 27520560, PMID 27784746, PMID 27890801, PMID 28246207
2017 (13), 2019 (12), 2018 (11), 2015 (7), 2014 (5), 2009 (4), 2016 (4), 2023 (4), P30CA015704 (3), P30CA016672 (3), 2008 (2), 2025 (2), N01CM17003 (2), N01CM62202 (2), P30CA060553 (2)